氯沙坦联合苯那普利对早期糖尿病肾病患者血浆APN及hs-CRP的影响

Effects of losartan combined with benazepril on plasma adiponectin and hs-CRP levels of patients with diabetic nephropathy in early stage

目的研究苯那普利联合氯沙坦对2型糖尿病肾病患者血浆脂联素（APN）及高敏C反应蛋白（hs—CRP）的影响。方法选择我院心血管内科住院的早期2型糖尿肾病患者84例，随机分为苯那普利组（常规组）及苯那普利联合氯沙坦组（联合组）各42例。常规组给予苯那普利10—20mg／d，治疗6个月；联合组给予苯那普利10mg／d，联合氯沙坦50—100mg／d，治疗6个月。分别检测两组患者入院、治疗3和6个月的血浆APN、hs—CRP变化。结果治疗后两组血浆APN较前入院前明显升高，hs-CRP明显减低（P〈0．05）。治疗3及6个月后，联合组血浆APN水平较常规组明显升高，hs-CRP较常规组明显减低（P〈0．05）。结论双重RAS阻滞剂具有明显肾保护作用，可升高2型糖尿病肾病患者血浆APN水平，降低血浆hs—CRP水平。

Objective To investigate the effects of benazepril combined with losartan on serum adiponectin （APN） and high sensitivity C-reactive protein（hs-CRP） levels in patients with type 2 diabetic nephropathy （DN）. Methods Eighty four patients with type 2 diabetic nephropathy were selected and randomly divided into benazepril group （ conventional group） and benazepril combined with losartan group（ combination group） with 42 cases in each group. The conventional group received benazepril 10-20 mg/day for 6 months. The combination group received benazepril 10 mg/day and losartan 50-100 mg/day for 6 months. Detection was made in the changes of plasma APN and hs-CRP in those patients at the time of admission and 3 and 6 months after the treatment. Results After the treatment, APN level of both groups significantly increased, and hs-CRP level significantly decreased （ P 〈 O. 05 ）. Three and six months after the treatment, APN level of the combination group significantly increased compared with that of the conventional group, and hs-CRP level significantly decreased（P 〈 0.05）. Conclusion Double RAS block agents have obvious protective effect on kidney, and can increase the plasma APN level and decrease the hs-CRP level in patients with type 2 diabetic nephropathy.